Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

abstract：:The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

journal_title：Expert review of neurotherapeutics

authors： Bilsky MH

更新日期：2005-11-01 00:00:00

abstract：INTRODUCTION:Neuromodulation techniques play an increasing role in the treatment of primary headaches. While initially reserved for refractory cases they are now increasingly taken into consideration in earlier treatment phases and in non-refractory situations. One of the main reasons for this paradigm shift is that mo...

journal_title：Expert review of neurotherapeutics

authors： Hoffmann J,May A

更新日期：2019-03-01 00:00:00

abstract：:The saga of harmful administration of levodopa (LD) in the treatment of Parkinson's disease (PD) resulted from outcomes of animal trials and cell culture studies. They were initiated after the clinical observation of onset of motor complications related to the short plasma half-life of the drug in PD patients. This di...

journal_title：Expert review of neurotherapeutics

authors： Müller T

更新日期：2008-06-01 00:00:00

abstract：:Systemic thrombolysis with recombinant tissue plasminogen activator is the first therapy proven to be effective in acute ischemic stroke. Nevertheless, its efficacy and feasibility are still a matter of debate. Much of this debate derives from uncertainties regarding patient eligibility and problems implementing this ...

journal_title：Expert review of neurotherapeutics

authors： Koennecke HC

更新日期：2002-03-01 00:00:00

abstract：:Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

journal_title：Expert review of neurotherapeutics

authors： Makke Y,Abou-Khalil B

更新日期：2019-10-01 00:00:00

abstract：:The aim of this article is to provide an overview on neuromuscular blocking agents and a rational selection of the most appropriate agents, along with pharmacological and pharmacoeconomic considerations on neuromuscular blockers and their antagonists. Neuromuscular blocking agents are used during anesthesia to facilit...

journal_title：Expert review of neurotherapeutics

authors： Leykin Y,Pellis T,Vincenti E

更新日期：2006-12-01 00:00:00

abstract：:Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. ...

journal_title：Expert review of neurotherapeutics

authors： Chen JX,Yan SD

更新日期：2007-11-01 00:00:00

abstract：:Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

journal_title：Expert review of neurotherapeutics

authors： Hill SK,Bishop JR,Palumbo D,Sweeney JA

更新日期：2010-01-01 00:00:00

abstract：:Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

journal_title：Expert review of neurotherapeutics

authors： Naoi M,Maruyama W

更新日期：2009-08-01 00:00:00

abstract：:There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

journal_title：Expert review of neurotherapeutics

authors： Michelsen JW,Meyer JM

更新日期：2007-07-01 00:00:00

abstract：INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...

journal_title：Expert review of neurotherapeutics

authors： Fernández-De-Las-Peñas C,Arendt-Nielsen L

更新日期：2017-09-01 00:00:00

abstract：:Patients with von Hippel-Lindau disease (VHL) often harbor significant disease burden within the CNS, specifically craniospinal-axis hemangioblastomas and endolymphatic sac tumors (ELSTs). The majority (60-80%) of patients with VHL harbor hemangioblastomas, and 10-15% will develop ELSTs. Advances in the understanding ...

journal_title：Expert review of neurotherapeutics

authors： Wind JJ,Lonser RR

更新日期：2011-10-01 00:00:00

abstract：:Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...

journal_title：Expert review of neurotherapeutics

authors： Scarr E,Dean B

更新日期：2009-01-01 00:00:00

abstract：:The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a ...

journal_title：Expert review of neurotherapeutics

authors： Bessaguet F,Magy L,Desmoulière A,Demiot C

更新日期：2016-01-01 00:00:00

abstract：:Poor insight or unawareness of illness has been commonly observed in schizophrenia and has been long recognized as a potent barrier to treatment adherence and a risk factor for a range of poorer outcomes. Paradoxically, the achievement of insight often poses a different set of problems including depression and low sel...

journal_title：Expert review of neurotherapeutics

authors： Lysaker PH,Vohs J,Hillis JD,Kukla M,Popolo R,Salvatore G,Dimaggio G

更新日期：2013-07-01 00:00:00

abstract：:Advances in molecular biology and virology in recent years have enabled the technology of gene transfer to proceed forward. Parkinson's disease (PD) is a particularly appropriate target for gene therapy since the brain pathology is fully characterized and relatively well circumscribed largely within the nigrostriatal ...

journal_title：Expert review of neurotherapeutics

authors： Mochizuki H

更新日期：2007-08-01 00:00:00

abstract：:Social anxiety disorder (SAD) is a prevalent, disabling disorder. We aimed to assess the effects of pharmacotherapy for SAD and to determine whether particular classes of medication are more effective and/or better tolerated than others. A systematic review and meta-analysis was conducted of all published and unpublis...

journal_title：Expert review of neurotherapeutics

authors： Ipser JC,Kariuki CM,Stein DJ

更新日期：2008-02-01 00:00:00

abstract：:The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and ...

journal_title：Expert review of neurotherapeutics

authors： Kornstein SG

更新日期：2008-05-01 00:00:00

abstract：:Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they have limitations that may affect our perception of disease progression either due to the empirical nature of some assessments or the lack of validation with lon...

journal_title：Expert review of neurotherapeutics

authors： Kieseier BC

更新日期：2014-01-01 00:00:00

abstract：:The prognosis for patients with malignant glioma, the most common primary intracranial neoplasm, remains dismal despite significant progress in neuro-oncological therapies and technology. This stems from the inability of current treatment strategies to address the highly invasive nature of this disease. Malignant glia...

journal_title：Expert review of neurotherapeutics

authors： Ehtesham M,Kabos P,Black KL,Yu JS

更新日期：2003-11-01 00:00:00

abstract：:Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

journal_title：Expert review of neurotherapeutics

authors： Tatum WO

更新日期：2006-07-01 00:00:00

abstract：:Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

journal_title：Expert review of neurotherapeutics

authors： Dorfman BJ,Jimenez-Shahed J

更新日期：2021-01-01 00:00:00

abstract：:Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

journal_title：Expert review of neurotherapeutics

authors： Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

更新日期：2011-02-01 00:00:00

abstract：:Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and generally well-tolerated method of focally stimulating brain regions. It has been shown to be efficacious in the treatment for depression, but only to a limited degree. It has also been investigated for the treatment of some anxiety disorders, pa...

journal_title：Expert review of neurotherapeutics

authors： Pigot M,Loo C,Sachdev P

更新日期：2008-10-01 00:00:00

abstract：:Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...

journal_title：Expert review of neurotherapeutics

authors： Pascual J,Vila C

更新日期：2019-08-01 00:00:00

abstract：:The risk of recurrent stroke following transient ischemic attack or minor stroke has recently been shown to be 5-10% at 1 week and 10-20% at 3 months, depending on study population and methods. This is considerably higher than previously estimated and current clinical guidelines reflect the need for rapid assessment a...

journal_title：Expert review of neurotherapeutics

authors： Giles MF,Rothwell PM

更新日期：2005-03-01 00:00:00

abstract：:Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

journal_title：Expert review of neurotherapeutics

authors： Sharma V,Sharma P,Sharma S

更新日期：2020-04-01 00:00:00

abstract：:Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...

journal_title：Expert review of neurotherapeutics

authors： Nieratschker V,Meyer-Lindenberg A,Witt SH

更新日期：2011-07-01 00:00:00

abstract：:Anaplastic glioma (AG) is divided into three morphology-based groups (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma) as well as three molecular groups (glioma-CpG island methylation phenotype [G-CIMP] negative, G-CIMP positive non-1p19q codeleted tumors and G-CIMP positive codeleted...

journal_title：Expert review of neurotherapeutics

authors： Le Rhun E,Taillibert S,Chamberlain MC

更新日期：2015-06-01 00:00:00

abstract：:Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...

journal_title：Expert review of neurotherapeutics

authors： Pettegrew JW,McClure RJ

更新日期：2002-09-01 00:00:00